Journal article
The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Abstract
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Application (BLA) for use of the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty (Pfizer, Inc.), in persons aged ≥16 years (1). The …
Authors
Woodworth KR; Moulia D; Collins JP; Hadler SC; Jones JM; Reddy SC; Chamberland M; Campos-Outcalt D; Morgan RL; Brooks O
Journal
MMWR Morbidity and Mortality Weekly Report, Vol. 70, No. 45, pp. 1579–1583
Publisher
Centers for Disease Control MMWR Office
DOI
10.15585/mmwr.mm7045e1
ISSN
0149-2195